NeuroDiscovery makes market debut
Monday, 15 August, 2005
Perth-based neurology-focused biotech company NeuroDiscovery (ASX:NDL) listed today on the Australian Stock Exchange at AUD$0.21, one cent above its issue price of $0.20.
NeuroDiscovery's IPO raised AUD$1.5 million through the issue of 36 million shares, and the company has finalised purchase of UK-based NeuroSolutions, which has a mature pipeline of programs for the treatment of pain.
"We are very pleased that we have been able to buy NeuroSolutions and welcome the University of Warwick as our major shareholder. As this is the first successful spin-out of the university we look forward to working with them in the next few years." said NeuroDiscovery chairman David McAuliffe.
At the time of writing, shares were trading at $0.20.
Anti-inflammatory drug may help treat alcohol use disorder
A drug that is already FDA-approved for treating inflammatory conditions may help reduce both...
Osteoarthritis study uncovers new genetic links, drug targets
The genome-wide association study (GWAS) uncovered over 900 genetic associations, more than 500...
How brain cells are affected by Tourette syndrome
US researchers have conducted a cell-by-cell analysis of brain tissue from individuals with...
